IT solutions provider Medidata honoured at Singapore awards

Medidata provides integrated solutions for clinical trial data management

Medidata was recognised with the Asia Pacific (APAC) Clinical Trial IT Solutions Provider of the Year Award at the annual Frost & Sullivan Asia-Pacific Best Practices Awards banquet in Singapore.

“Medidata is a prominent participant in the clinical trials IT solutions market, providing integrated solutions for clinical trial data management through a cloud-based unified platform with pioneering analytics,” said Aarti Chitale, senior research analyst at Frost & Sullivan.

The provider applies artificial intelligence and advanced analytics to deliver insights to over 1,100 customers across every therapeutic area and clinical phase, with a customer base ranging from emerging biotech to more established pharmaceutical and contract research organisations (CRO).

"The company's machine learning algorithm and a complete suite of services enable robust financial performance and elevate it to a leading technology solution provider in the clinical trial industry,” added Chitale.

“By adopting a collaborative business model, Medidata is establishing itself as a vital player in the global clinical trial IT market."

The recipients of the annual Frost & Sullivan APAC Best Practice Awards were identified based on in-depth research conducted by the its analysts.

The award categories offered each year are reviewed and evaluated to reflect the current market landscape and include new emerging trends.

The short-listed companies were evaluated on a variety of actual market performance indicators which include revenue growth; market share and growth in market share; leadership in product innovation; marketing strategy and business development strategy.

“We are proud to be named the 2018 Asia Pacific Clinical Trial IT Solutions Provider of the Year by Frost & Sullivan,” said Julie Iskow, executive vice president of product development and CTO, Medidata.

“This award recognises our commitment to accelerating the delivery of new therapies to patients around the world."